Aethlon Medical (NASDAQ:AEMD) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a report on Friday, November 15th.

Aethlon Medical Stock Performance

NASDAQ:AEMD opened at $0.66 on Wednesday. The company has a fifty day moving average of $0.39 and a two-hundred day moving average of $0.42. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $2.35. The stock has a market capitalization of $9.22 million, a PE ratio of -0.23 and a beta of 1.79.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.